HRP20120085T1 - Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu - Google Patents

Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu Download PDF

Info

Publication number
HRP20120085T1
HRP20120085T1 HR20120085T HRP20120085T HRP20120085T1 HR P20120085 T1 HRP20120085 T1 HR P20120085T1 HR 20120085 T HR20120085 T HR 20120085T HR P20120085 T HRP20120085 T HR P20120085T HR P20120085 T1 HRP20120085 T1 HR P20120085T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
weight
amount
preparation according
cancer
Prior art date
Application number
HR20120085T
Other languages
English (en)
Croatian (hr)
Inventor
David Blyth John
John Day Andrew
James Lennon Kieran
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120085(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20120085T1 publication Critical patent/HRP20120085T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20120085T 2007-10-12 2008-10-09 Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu HRP20120085T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15
PCT/GB2008/050928 WO2009047565A2 (en) 2007-10-12 2008-10-09 Composition 064

Publications (1)

Publication Number Publication Date
HRP20120085T1 true HRP20120085T1 (hr) 2012-02-29

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120085T HRP20120085T1 (hr) 2007-10-12 2008-10-09 Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu

Country Status (34)

Country Link
US (2) US8168221B2 (de)
EP (2) EP2209501B1 (de)
JP (1) JP2011500548A (de)
KR (1) KR20100099113A (de)
CN (1) CN101896210A (de)
AR (1) AR068845A1 (de)
AT (1) ATE536893T1 (de)
AU (1) AU2008309385B2 (de)
BR (1) BRPI0818323A2 (de)
CA (1) CA2701385A1 (de)
CL (1) CL2008003022A1 (de)
CO (1) CO6270344A2 (de)
CR (1) CR11363A (de)
CU (1) CU20100064A7 (de)
CY (1) CY1112433T1 (de)
DK (1) DK2209501T3 (de)
DO (1) DOP2010000105A (de)
EA (1) EA201000545A1 (de)
ES (1) ES2377426T3 (de)
HR (1) HRP20120085T1 (de)
IL (1) IL204953A0 (de)
MX (1) MX2010003989A (de)
NI (1) NI201000052A (de)
NZ (1) NZ585310A (de)
PE (1) PE20091032A1 (de)
PL (1) PL2209501T3 (de)
PT (1) PT2209501E (de)
SG (1) SG182138A1 (de)
SI (1) SI2209501T1 (de)
SV (1) SV2010003529A (de)
TW (1) TW200924768A (de)
UY (1) UY31385A1 (de)
WO (1) WO2009047565A2 (de)
ZA (1) ZA201002477B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
EP2209501B1 (de) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan Zusammensetzung mit Mannitol und Mikrokristalliner Zellulose
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
WO2011143347A2 (en) * 2010-05-11 2011-11-17 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
CN104244931A (zh) * 2012-04-27 2014-12-24 默克专利股份有限公司 经包衣的片剂及其制备
US9115085B2 (en) 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IL296484B2 (en) * 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
DK4331607T3 (da) 2015-12-02 2025-05-19 Nippon Shinyaku Co Ltd Fast farmaceutisk sammensætning indeholdende 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamid
MX2022011215A (es) * 2020-03-31 2022-10-07 Eisai R&D Man Co Ltd Comprimido, medicamento, metodos para producirlos y kit.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6432994B1 (en) * 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6740339B1 (en) * 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
US20030100595A1 (en) 2001-11-13 2003-05-29 Aziz Karim Oral dosage form of a sulfonamide prodrug
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JP2006504696A (ja) * 2002-09-20 2006-02-09 メルク　エンド　カムパニー　インコーポレーテッド インテグリン受容体アンタゴニストのマンニトール製剤
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
EP2209501B1 (de) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan Zusammensetzung mit Mannitol und Mikrokristalliner Zellulose

Also Published As

Publication number Publication date
JP2011500548A (ja) 2011-01-06
PL2209501T3 (pl) 2012-03-30
EA201000545A1 (ru) 2010-10-29
CN101896210A (zh) 2010-11-24
UY31385A1 (es) 2009-05-29
NI201000052A (es) 2011-03-24
MX2010003989A (es) 2010-04-27
TW200924768A (en) 2009-06-16
CL2008003022A1 (es) 2010-07-23
CR11363A (es) 2010-07-14
DOP2010000105A (es) 2010-08-15
US8168221B2 (en) 2012-05-01
AU2008309385B2 (en) 2011-10-20
ES2377426T3 (es) 2012-03-27
AR068845A1 (es) 2009-12-09
EP2209501B1 (de) 2011-12-14
WO2009047565A3 (en) 2009-11-26
PE20091032A1 (es) 2009-08-15
SG182138A1 (en) 2012-07-30
EP2209501A2 (de) 2010-07-28
CY1112433T1 (el) 2015-12-09
CO6270344A2 (es) 2011-04-20
EP2433620A1 (de) 2012-03-28
DK2209501T3 (da) 2012-02-27
WO2009047565A2 (en) 2009-04-16
HK1143095A1 (en) 2010-12-24
AU2008309385A1 (en) 2009-04-16
CA2701385A1 (en) 2009-04-16
SI2209501T1 (sl) 2012-03-30
KR20100099113A (ko) 2010-09-10
CU20100064A7 (es) 2011-10-05
ATE536893T1 (de) 2011-12-15
NZ585310A (en) 2012-02-24
BRPI0818323A2 (pt) 2017-05-16
IL204953A0 (en) 2010-11-30
US20120177705A1 (en) 2012-07-12
SV2010003529A (es) 2010-09-13
PT2209501E (pt) 2012-02-03
ZA201002477B (en) 2010-12-29
US20090099203A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
MX2010014234A (es) Compuestos pirazol 436.
RU2013151904A (ru) Применение соединений мышьяка для лечения отторжения ткани или органа
MX2010005087A (es) Formulacion solida de liberacion rapida, preparacion y uso de la misma.
AR068845A1 (es) Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
PE20061345A1 (es) Composicion farmaceutica que comprende sorafenib
GEP20135983B (en) 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression
HRP20192026T4 (hr) Formulacija tableta od neratinib maleata
NZ727015A (en) Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
RU2011117177A (ru) ДОЗИРОВАННЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ 3-(6-(1-(2,2-ДИФТОРБЕНЗО[d][1,3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ
TW200801029A (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
JP2010132654A5 (de)
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
NZ702159A (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
BR112014018355A8 (pt) Composto inibidor de quinase reguladora de sinal de apoptose, composição farmacêutica compreendendo o referido composto, uso e compostos intermediários do mesmo
MX2009009153A (es) Pirano-pirazol-aminas.
PE20130657A1 (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
NZ608558A (en) Pharmaceutical compositions containing a dgat1 inhibitor